David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley acquired 40,000 shares of the stock in a transaction on Monday, December 16th. The stock was acquired at an average cost of C$1.88 per share, for a total transaction of C$75,072.00.

Cardiol Therapeutics Stock Up 0.8 %

CRDL opened at C$1.91 on Tuesday. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. Cardiol Therapeutics Inc. has a 12 month low of C$1.07 and a 12 month high of C$4.26. The stock has a market capitalization of C$133.12 million, a P/E ratio of -4.33 and a beta of 0.70. The business has a 50 day simple moving average of C$2.43 and a 200-day simple moving average of C$2.74.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.